- Home
- NVR vs BIIB Comparison
NVR vs BIIB Comparison
Compare NVR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVR
- BIIB
- Stock Information
- Founded
- NVR 1980
- BIIB 1978
- Country
- NVR United States
- BIIB United States
- Employees
- NVR N/A
- BIIB N/A
- Industry
- NVR Homebuilding
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- NVR Consumer Discretionary
- BIIB Health Care
- Exchange
- NVR Nasdaq
- BIIB Nasdaq
- Market Cap
- NVR 28.2B
- BIIB 25.1B
- IPO Year
- NVR N/A
- BIIB 1991
- Fundamental
- Price
- NVR $8,948.92
- BIIB $157.78
- Analyst Decision
- NVR Buy
- BIIB Buy
- Analyst Count
- NVR 3
- BIIB 25
- Target Price
- NVR $10,025.00
- BIIB $258.57
- AVG Volume (30 Days)
- NVR 21.7K
- BIIB 1.6M
- Earning Date
- NVR 01-28-2025
- BIIB 10-30-2024
- Dividend Yield
- NVR N/A
- BIIB N/A
- EPS Growth
- NVR 2.79
- BIIB 10.05
- EPS
- NVR 488.66
- BIIB 11.06
- Revenue
- NVR $10,281,399,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- NVR $6.32
- BIIB N/A
- Revenue Next Year
- NVR $5.91
- BIIB N/A
- P/E Ratio
- NVR $18.31
- BIIB $14.26
- Revenue Growth
- NVR 3.41
- BIIB N/A
- 52 Week Low
- NVR $6,434.99
- BIIB $153.62
- 52 Week High
- NVR $9,964.77
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- NVR 40.55
- BIIB 33.43
- Support Level
- NVR $9,100.00
- BIIB $158.44
- Resistance Level
- NVR $9,256.14
- BIIB $162.62
- Average True Range (ATR)
- NVR 177.93
- BIIB 3.19
- MACD
- NVR -2.44
- BIIB 0.90
- Stochastic Oscillator
- NVR 33.40
- BIIB 35.65
About NVR NVR Inc.
NVR Inc is a United States-based homebuilding company. It builds single-family detached homes, townhomes, and condominium buildings under three brands, Ryan Homes, NVHomes, and Heartland Homes. The company through its subsidiary also operates a mortgage banking and title services business. The homebuilding segment includes four geographic areas of the United States; Mid-Atlantic, North East, Mid-East, and South East.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.